Uric acid (urate) has been suggested to play a protective role in Parkinson's disease onset through its antioxidant activity. Dysfunction of ABCG2, a highcapacity urate exporter, is a major cause for early-onset gout based on hyperuricemia. In this study, the effects of a dysfunctional ABCG2 variant (Q141K, rs2231142) were analyzed on the ages at onset of gout patients (N = 507) and Parkinson's disease patients (N = 1015). The Q141K variant hastened the gout onset (P = 0.0027), but significantly associated with later Parkinson's disease onset (P = 0.025). Our findings will be helpful for development of more effective prevention of Parkinson's disease.
Introduction
Parkinson's disease (PD) is a multifactorial disease characterized by selective cell death of dopaminergic neurons. Oxidative stress is well known to be one of the major causes of PD development. 1 On the other hand, uric acid (UA), which has an antioxidant effect on the central nervous system (CNS), may play a protective role in onset and development of PD. 2, 3 Gout, a consequence of hyperuricemia, is also associated with a lower risk of PD. 4 Previously, common dysfunctional variants of ATP-binding cassette transporter, sub-family G, member 2 (ABCG2, also known as BCRP), a urate transporter gene, 5, 6 have been revealed to be a major cause of early-onset gout. 7 The common variant (Q141K, rs2231142) of ABCG2 is proven to be a dysfunctional variant by in vitro functional studies. 5, 6 This study aimed to evaluate whether the Q141K variant of ABCG2 could delay the age at onset (AAO) of PD in a relatively large population of Japanese patients. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Patients and Methods

Study participants
This study was approved by the institutional ethical committees, and all procedures involved in this study were performed in accordance with the Declaration of Helsinki. Informed consent in writing was obtained from each subject participating in this study. A total of 1015 PD patients (464 male and 548 female) and 507 gout male patients was collected and then genetically analyzed. PD patients were collected in Juntendo University (Tokyo, Japan) and Kobe University (Kobe, Japan). Diagnosis of PD was made by board-certified neurologists of the Japanese Society of Neurology, based on the presence of at least two cardinal features of PD with no secondary cause, no levodopa unresponsiveness, or no early signs of more extensive nervous system involvement. 8 Clinically defined gout cases were collected in the Kyoto Industrial Health Association (Kyoto, Japan).
Genetic analysis
Genomic DNA was extracted from whole peripheral blood cells. 9 For PD patients, genotyping of Q141K (rs2231142) in ABCG2 gene was performed by direct sequencing using the following primers: forward, 5
0 -AT-GGAGTTAACTGTCATTTGC-3 0 , and reverse, 5 0 -CAC-GTTCATATTATGTAACAAGCC-3 0 . DNA sequencing analysis was performed with a 3130xl Genetic Analyzer 10 (Life Technologies Corporation, Carlsbad, CA). The genotyping data of PD patients collected in Kobe University were obtained from the result of previous GWAS 11 using the Illumina Infinium HumanHap550 array (Illumina, Inc., San Diego, CA). For gout patients, genotyping of Q141K in ABCG2 gene was performed by TaqMan assay (Life Technologies Corporation) with a LightCycler 480 (Roche Diagnostics, Mannheim, Germany).
12,13
Statistical analysis
In the statistical analysis, SPSS v.17.0J (IBM Japan Inc., Tokyo, Japan) was used for all calculations. Regression analysis was used for the association analysis.
Results
The results of genotyping of gout and PD patients are shown in Table 1 . Figure 1 shows the AAO of gout and PD participants of each genotype of ABCG2 Q141K. The AAO (mean AE standard error) of gout were 40.4 AE 1.1 years old, 42.0 AE 0.7 years old, and 45.0 AE 1.1 years old for patients with Q141K homozygous (A/A), heterozygous (C/A) mutation, and without Q141K mutation (C/C), respectively. On the other hand, the AAO of PD were 58.5 AE 1.1 years old, 58.2 AE 0.5 years old, and 56.6 AE 0.5 years for patients with Q141K homozygous, heterozygous mutation, and without mutation, respectively. The AAO of gout with homozygous mutation was 4.6 years younger than those without Q141K mutation, while the AAO of PD with homozygous mutation was 1.6 years older than those without Q141K mutation.
The Q141K mutation of ABCG2 hastened the onset of gout significantly (P = 0.0027; see 
Discussion
This study revealed for the first time that a common dysfunctional variant of ABCG2 (Q141K, rs2231142) has surprisingly differential effects on two common diseases, significantly delaying the AAO of PD, while hastening that of gout. ABCG2 encodes ATP-dependent transporter for urate excretion both in gut 14, 15 and kidney. 16 Molecular functional studies revealed that ABCG2 dysfunction elevates serum UA levels. 5, 6 As UA is the strong antioxidant, ABCG2 dysfunction might have a neuroprotective effect. In fact, our study showed that the dysfunctional variant of this UA-related gene, ABCG2, could have a protective effect against PD, which is wholly consistent with the previous studies suggesting that the higher levels of serum UA are negatively correlated with the risk of PD 17 and its rate of progression. 18 So far, only a few genetic analyses have been performed about the association between PD onset and UA-related genes. 19, 20 However, there is no report demonstrating that Together with the antioxidant effect of UA, our results strongly support the hypothesis that UA should reduce the risk of PD as an antioxidant, because oxidative stress is involved in the pathogenesis of PD. In addition to its expression in gut and kidney, ABCG2 highly expresses in the blood brain barrier (BBB). 21 Therefore, we propose a physiological model that ABCG2 exports urate from the brain side to the blood side at BBB (see Fig. 2 ). Since ABCG2 dysfunction decreases urate excretion via gut 14, 15 and kidney, 16 which results in serum UA elevation, 5, 6, 14, 16 it therefore has a pathogenic effect on earlier onset of gout. Elevated serum UA also should result in elevated UA levels in CNS. In addition, ABCG2 dysfunction could decrease urate excretion via BBB that enhances the Figure 1 . ABCG2 dysfunctional variant (Q141K) and the age at onset (AAO) of gout/PD. The AAO of gout was significantly hastened as the number of minor alleles of Q141K increased (P = 0.0027); on the contrary, the AAO of PD was significantly delayed as the number of minor alleles of Q141K increased (P = 0.025). The AAO of gout with homozygous mutation (A/A) was 4.6 years younger than those without Q141K mutation (C/C). And the AAO of PD with homozygous mutation was 1.6 years older than those without Q141K mutation. Each bar represents the mean with standard error. elevation of UA levels in CNS as shown in our proposed model (see Fig. 2 ). In this model, ABCG2 dysfunction coordinately increases UA levels in CNS by the combined two differential mechanisms shown in Figure 2 , although other UA-related gene variants have not been reported to have such differential mechanisms to elevate UA levels in CNS. Thus, the dysfunction of ABCG2 both in gut/kidney and BBB could cooperatively contribute to the elevated UA levels in CNS. These proposed differential mechanisms are consistent with our present result, which showed the differential effects on AAO of two common diseases, gout and PD. By these two differential mechanisms, therefore, ABCG2 dysfunction could have a significant neuroprotective effect for later onset of PD through increased UA, the strong antioxidant (see Fig. 2 ). That is why ABCG2 dysfunction could have significant effects on PD and be important in PD pathogenesis. Furthermore, the regulation of UA levels in serum and CNS could be applicable for prevention and therapy of PD. 22 
